CTMX cytomx.com: Enterprise Value to EBITDA Ratio

Brandmark of CytomX Therapeutics (CTMX)

The stock price retrospective for CytomX Therapeutics (CTMX) demonstrates an EV/EBITDA of 0.00. CytomX Therapeutics develops solutions for the targeted destruction of tumors through collaborations with industry behemoths. The current drug portfolio minimizes side effects via the local activation of therapy. Meanwhile, the business relies on external contractors for manufacturing and testing, maintaining its status as a mobile research center.

CTMX CytomX Therapeutics Inc: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/11/2026

Metric breakdowns and analytics for cytomx.com (CTMX)

- stock price and consensus target price:
Stock Quotes CytomX Therapeutics Inc|CTMX - Average Forecast Price
- company stock capitalization data:
Market Valuation CytomX Corp|CTMX - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share CytomX Therapeutics|CTMX - Net Asset Value|Market Value to Book Value Ratio cytomx.com|CTMX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital CytomX Therapeutics|CTMX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio CytomX Therapeutics, Inc.|CTMX - Company Cumulative Indebtedness|Debts to Book Capitalization CytomX Corp|CTMX - Long-Term Liabilities|Company Short-Term Debt CytomX Therapeutics|Quick Liquidity cytomx.com
- business earnings and investment ratios data:
CTMX - Final Profit|Expected Profit CytomX Therapeutics|CTMX - Price to Earnings Ratio|Future Price to Earnings CytomX Therapeutics|CTMX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple CytomX Corp|CTMX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months CytomX Therapeutics|CTMX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cytomx.com|CTMX - Net earnings per one share growth for the current year|Net earnings per share growth forecast for next year CytomX Therapeutics
General company analysis:CytomX Therapeutics Inc CTMX
Product sample of CytomX Pharma

CytomX Therapeutics (CTMX) develops oncology programs through external funding from strategic partners. The enterprise value to EBITDA multiple compares the total asset price to its cash flow, excluding the impact of taxes and debt load. This chart's price action allows for the filtering of market noise to assess the real value of the business. The stability of this indicator confirms the company's fundamental resilience.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CATX (Perspective Therapeutics)|genelux.com (GNLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MOLN (Molecular Partners Ltd)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio